<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162821</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F351-201902</org_study_id>
    <nct_id>NCT04162821</nct_id>
  </id_info>
  <brief_title>Study on Pharmacokinetics of Hydronidone</brief_title>
  <official_title>Clinical Pharmacokinetics of Hydroxynitone Capsules in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetic characteristics of hydronidone capsules (specification: 30&#xD;
      mg/ pill) in healthy subjects And the effect of feeding on pharmacokinetics to provide&#xD;
      evidence for phase II/III clinical trial protocols.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">November 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma drug concentration</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Plasma drug concentration after administration of different doses of hydronidone</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pharmacokinetics of Hydronidone</condition>
  <arm_group>
    <arm_group_label>60mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>90mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>120mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydronidone</intervention_name>
    <description>Take hydroxynitone capsule</description>
    <arm_group_label>120mg group</arm_group_label>
    <arm_group_label>60mg group</arm_group_label>
    <arm_group_label>90mg group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy volunteers, half male and half female;&#xD;
&#xD;
          2. Age: from 18 to 45 years old, the age difference of the same group of subjects should&#xD;
             not be more than 10 years;&#xD;
&#xD;
          3. Weight: male ≥50kg, female ≥45kg, 19≤BMI≤24 (BMI= weight (kg)/height 2 (m2));&#xD;
&#xD;
          4. Complete physical examination: vital signs, hematuria routine, blood pregnancy, blood&#xD;
             glucose, blood lipid,Blood electrolyte, hepatitis b surface antigen, liver and kidney&#xD;
             function, hepatitis c, HIV and syphilis antibody test, Electrocardiogram, smoke test,&#xD;
             urine drug screening, alcohol breath test, abdominal ultrasound examination, chest&#xD;
             X-ray examination No abnormal or abnormal clinical significance;&#xD;
&#xD;
          5. Detailed understanding of the nature, significance, possible benefits and possible&#xD;
             disadvantages of the experiment has been obtained before the study I was able to&#xD;
             communicate well with the researchers, Comply with the requirements of the entire&#xD;
             study and be able to understand and sign written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have participated in any other clinical trials within the first three months of the&#xD;
             trial;&#xD;
&#xD;
          2. Any diseases that may affect the safety of the test or the process of the drug in&#xD;
             vivo, including But not limited to: heart, liver, kidney, endocrine, digestive tract,&#xD;
             immune system and respiratory system Those with or existing diseases of the above&#xD;
             system (especially those with cardiovascular diseases including cardiovascular&#xD;
             diseases) Any gastrointestinal disease that affects drug absorption (such as irritable&#xD;
             bowel syndrome symptoms, inflammation) History of sexual bowel), active pathological&#xD;
             bleeding (such as peptic ulcer), urticaria, epilepsy, past Allergic rhinitis, eczema&#xD;
             dermatitis, asthma, etc.&#xD;
&#xD;
          3. (consultation) allergy: if there are two or more drugs, food allergies or lactose&#xD;
             intolerance Tolerance;&#xD;
&#xD;
          4. (consultation) any inhibition or induction of liver administration during the first 28&#xD;
             days of administration of the study drug Drugs for metabolism (common liver enzyme&#xD;
             inducers: barbiturates Drugs for metabolism (common liver enzyme inducers:&#xD;
             barbiturates such as phenobarbital, carbamazepine,Aminorumide, griseofulvin,&#xD;
             aminopropyl, phenytoin, gluconate, rifampicin, desicer Betamethasone. Common liver&#xD;
             enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chlorine&#xD;
             Mycin, isoniazid, sulfonamide, etc. Or had used any medication (pack) within 14 days&#xD;
             prior to initial administration Including Chinese herbal medicine and health products;&#xD;
&#xD;
          5. (consultation) have specific food requirements and cannot follow a uniform diet (such&#xD;
             as standard meals or high fat) Food intolerance) or difficulty swallowing;&#xD;
&#xD;
          6. (consultation) unable to tolerate venipuncture and/or having a history of blood or&#xD;
             acupuncture;&#xD;
&#xD;
          7. (consultation) long-term overconsumption of tea and coffee (more than 8 cups a day, 1&#xD;
             cup =250mL) A person who drinks coffee or caffeine; Or 48 hours before the study's&#xD;
             first dose Foods or drinks with caffeine (such as coffee, strong tea, chocolate, etc.)&#xD;
             affect the absorption of drugs, A special diet of distribution, metabolism, and&#xD;
             excretion;&#xD;
&#xD;
          8. (consultation) previous binge drinking (i.e., drinking more than 28 units per week for&#xD;
             men and more than 28 units per week for women Drink more than 21 units of alcohol (1&#xD;
             unit contains 14 grams of alcohol, such as 360 mL of beer or 45 mL spirits of 40%&#xD;
             alcohol or 150 mL wine); Or within 6 months prior to the trial Regular drinkers (more&#xD;
             than 14 units per week); Or 24 before the first dose of the study Who has taken any&#xD;
             alcoholic product within an hour;&#xD;
&#xD;
          9. (consultation) study blood donation or massive bleeding (greater than 450 mL) within 3&#xD;
             months before initial administration. Or who plans to donate blood or blood components&#xD;
             during or within 3 months after the study;&#xD;
&#xD;
         10. (consultation) acute illness during the screening phase before study or before study&#xD;
             medication;&#xD;
&#xD;
         11. (consultation) study of patients with liver replacement containing drugs that induce&#xD;
             or inhibit liver replacement within 24 hours before initial administration Foods or&#xD;
             drinks containing enzymes (e.g., grapefruit, mango, pitaya, grape juice, orange juice,&#xD;
             etc.) are abundant Rich in flavonoids or citrus glycosides);&#xD;
&#xD;
         12. Surgery was performed within three months prior to the screening period or was planned&#xD;
             for the duration of the study Surgery;&#xD;
&#xD;
         13. (consultation) previous history of drug abuse; A history of drug abuse;&#xD;
&#xD;
         14. (consultation) smoking more than 5 cigarettes per day during the 14 days before&#xD;
             screening, or during the trial Using any tobacco products;&#xD;
&#xD;
         15. Screening of persons who have smoked or used any tobacco products up to admission;&#xD;
&#xD;
         16. Positive results of nicotine test;&#xD;
&#xD;
         17. Alcohol breath test with test results greater than 0.0mg/100ml;&#xD;
&#xD;
         18. Positive urine drug screening;&#xD;
&#xD;
         19. Pregnant women or those who plan to become pregnant within 6 months after the end of&#xD;
             the trial;&#xD;
&#xD;
         20. The investigator considers that there is anything that may affect the subject's&#xD;
             informed consent or adherence to the protocol Or participating in the test may affect&#xD;
             the results of the test or the safety of the personnel under test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ethics committee of drug clinical trials of huazhong university of science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

